Exudative Retinal Detachment – A Complete Patient Guide

Overview

Exudative retinal detachment (ERD), also called serous or non‑traumatic retinal detachment, occurs when fluid accumulates beneath the neurosensory retina without a retinal tear or break. The fluid originates from abnormal blood‑retinal barrier leakage, inflammation, or tumor‑related processes, causing the retina to separate from the underlying retinal pigment epithelium (RPE).

• Typical age: Can affect any age, but most cases are seen in adults aged 40–70 years.
• Gender: Slight male predominance in some series, largely reflecting the underlying diseases (e.g., central serous chorioretinopathy is more common in men).
• Prevalence: Exact population prevalence is unknown because ERD is usually reported as part of a broader retina‑detachment cohort. It accounts for roughly 5–10 % of all retinal detachments worldwide [1].

Unlike rhegmatogenous retinal detachment, which results from a retinal tear, ERD is driven by fluid leakage. Common underlying conditions include inflammatory eye disease, tumors (e.g., choroidal melanoma), vascular disorders, and systemic illnesses such as malignant hypertension.

Symptoms

Symptoms can develop suddenly or progress over days to weeks. The severity often mirrors the amount of sub‑retinal fluid and the part of the retina involved.

• Flashes of light (photopsia): Usually less frequent than in rhegmatogenous detachment.
• Sudden onset of blurred or dim vision: May be described as looking through a fog or “wet glass.”
• Visual field loss: Frequently a peripheral shadow that can expand toward the center.
• Metamorphopsia: Straight lines appear wavy or distorted, especially when the macula is involved.
• Central scotoma: A dark spot in the center of vision if the macula detaches.
• Colour perception changes: Colours may look washed‑out.
• Eye discomfort or pressure sensation: Uncommon but can occur with associated inflammation.

Because the visual changes can be subtle, many patients mistake early symptoms for a “dirty” lens or normal aging.

Causes and Risk Factors

ERD is usually a manifestation of another disease. The main categories are:

Inflammatory/Immune Disorders

• Posterior uveitis (e.g., Vogt‑Koyanagi‑Harada disease, sarcoidosis, Behçet’s disease)
• Idiopathic panuveitis
• Autoimmune conditions causing breakdown of the blood‑retina barrier

Vascular Causes

• Severe hypertensive retinopathy or malignant hypertension
• Ischemic central retinal vein occlusion (CRVO) with massive macular edema
• Choroidal vascular hyperpermeability (e.g., in central serous chorioretinopathy)

Neoplastic Processes

• Choroidal melanoma, metastases from breast or lung cancer
• Retinoblastoma (in children)

Other Systemic Conditions

• Systemic lupus erythematosus, autoimmune vasculitis
• Hyperthyroidism (thyroid eye disease)
• Pregnancy‑related changes (rare)

Risk Factors

• Existing ocular inflammation or a history of uveitis
• Uncontrolled hypertension or cardiovascular disease
• Use of systemic steroids or immunosuppressive drugs (may mask early inflammation)
• Exposure to tobacco and high‑dose corticosteroids (risk factors for central serous chorioretinopathy)
• Genetic predisposition for certain choroidal tumors

Diagnosis

Prompt diagnosis is essential to prevent permanent vision loss. An eye‑care professional will combine a detailed history, visual‑function testing, and imaging.

Clinical Examination

• Visual acuity testing: Quantifies central vision loss.
• Dilated fundus examination: Direct or indirect ophthalmoscopy reveals a smooth, dome‑shaped elevation of the retina without a retinal break.
• A‑scan/B‑scan ultrasonography: Detects sub‑retinal fluid and helps differentiate from other detachments.

Imaging Modalities

• Optical Coherence Tomography (OCT): High‑resolution cross‑sectional images that show fluid under the retina and can monitor response to therapy.
• Fluorescein Angiography (FA): Highlights leakage points from retinal vessels or choroidal neovascular membranes.
• Indocyanine Green Angiography (ICGA): Better visualises choroidal vasculature, useful for diagnosing choroidal tumors or VKH disease.
• Fundus Autofluorescence (FAF): Assesses RPE health; abnormal patterns may indicate chronic disease.

Systemic Work‑up (when indicated)

• Blood pressure measurement and basic metabolic panel
• Autoimmune panel (ANA, ACE, HLA‑B51, etc.) if inflammatory disease suspected
• Chest imaging for sarcoidosis
• Oncologic screening (CT, MRI, PET) when a tumor is suspected

Treatment Options

Treatment is disease‑specific; the primary goal is to eliminate the source of fluid leakage and re‑attach the retina.

Medical Management

• Corticosteroids: Systemic (prednisone 0.5–1 mg/kg) or intra‑vitreal (triamcinolone) to suppress inflammation in uveitis, VKH, or sarcoidosis. Taper slowly to avoid rebound.
• Immunomodulatory therapy (IMT): Agents such as methotrexate, azathioprine, mycophenolate mofetil, or biologics (e.g., adalimumab) for chronic or steroid‑dependent cases.
• Anti‑VEGF agents: Ranibizumab, aflibercept, or bevacizumab for choroidal neovascular membranes or severe CRVO‑related fluid.
• Systemic hypertension control: ACE inhibitors, ARBs, calcium‑channel blockers; target BP <130/80 mm Hg per ACC/AHA guidelines.
• Chemotherapy / radiation: For choroidal melanoma or metastatic lesions, according to oncologic protocols.

Surgical/Procedural Options

• Pneumatic retinopexy: Rarely used for ERD because there is no retinal break, but can be considered if a secondary tear develops.
• Pars plana vitrectomy (PPV) with internal drainage: Employed when sub‑retinal fluid is massive, chronic, or associated with tractional components.
• Scleral buckling: Typically for rhegmatogenous detachments; not first‑line for pure exudative cases.
• Sub‑retinal fluid drainage: Direct external drainage via a small retinotomy during PPV, occasionally combined with intra‑ocular tamponade (SF6 or C3F8 gas).

Lifestyle & Supportive Measures

• Strict blood‑pressure monitoring.
• Limit corticosteroid exposure unless prescribed.
• Smoking cessation – reduces vascular inflammation.
• Protect eyes from trauma and UV exposure (UV‑blocking sunglasses).
• Maintain a healthy weight and regular exercise to improve vascular health.

Living with Exudative Retinal Detachment

Even after successful treatment, many patients need ongoing care to preserve vision.

Follow‑up Schedule

• First month: visits every 1–2 weeks with OCT to ensure fluid resolution.
• Months 2–6: monthly exams if stable; quarterly thereafter.
• Life‑long annual retinal exam, or sooner if symptoms recur.

Vision‑Aid Strategies

• High‑contrast, large‑print reading materials.
• Electronic magnifiers or screen‑reader apps.
• Adaptive lighting (avoid glare, use task lighting).
• Occupational therapy for low‑vision patients.

Psychological Support

Sudden vision changes can provoke anxiety or depression. Encourage patients to seek counseling, join support groups, or use tele‑health mental‑health services.

Medication Adherence

Use pill organizers, set reminders, and keep a medication list handy. Discuss side‑effects promptly with the provider.

Prevention

Because ERD is largely secondary, primary prevention focuses on controlling the underlying conditions.

• Control systemic hypertension – regular BP checks, medication adherence, low‑salt diet.
• Manage diabetes and hyperlipidemia – these conditions increase vascular leakage.
• Prompt treatment of ocular inflammation – early referral for uveitis.
• Avoid unnecessary systemic steroids – if steroids are needed, use the lowest effective dose and taper under supervision.
• Regular eye examinations for high‑risk patients (e.g., those with known choroidal nevi, prior uveitis, or vascular disease).

Complications

If untreated or inadequately managed, ERD can lead to permanent visual impairment.

• Permanent retinal atrophy: Chronic sub‑retinal fluid damages photoreceptors.
• Secondary rhegmatogenous detachment: Fluid may cause retinal tears.
• Macular fibrosis or scar formation: Leads to irreversible central vision loss.
• Neovascular glaucoma: Especially in chronic inflammatory or tumor‑related cases.
• Systemic sequelae: Uncontrolled hypertension or untreated malignancy carries its own morbidity.

When to Seek Emergency Care

---

Sources: [1] American Academy of Ophthalmology. “Retinal Detachment.” 2023. [2] Mayo Clinic. “Exudative retinal detachment.” 2022. [3] National Eye Institute, NIH. “Uveitis and retinal diseases.” 2021. [4] WHO. “Global prevalence of hypertension.” 2021. [5] Cleveland Clinic. “Central serous chorioretinopathy.” 2023.